4.61
price up icon6.47%   0.28
after-market After Hours: 4.61
loading
Codexis Inc stock is traded at $4.61, with a volume of 680.47K. It is up +6.47% in the last 24 hours and up +39.70% over the past month. Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
See More
Previous Close:
$4.33
Open:
$4.37
24h Volume:
680.47K
Relative Volume:
1.06
Market Cap:
$375.15M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-5.4235
EPS:
-0.85
Net Cash Flow:
$-57.06M
1W Performance:
+18.81%
1M Performance:
+39.70%
6M Performance:
+32.85%
1Y Performance:
+135.20%
1-Day Range:
Value
$4.30
$4.695
1-Week Range:
Value
$3.715
$4.695
52-Week Range:
Value
$1.85
$4.91

Codexis Inc Stock (CDXS) Company Profile

Name
Name
Codexis Inc
Name
Phone
650-421-8100
Name
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Name
Employee
174
Name
Twitter
@codexisinc
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
CDXS's Discussions on Twitter

Compare CDXS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
CDXS 4.61 375.15M 70.14M -76.24M -57.06M -0.85
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Codexis Inc Stock (CDXS) Upgrades & Downgrades

Date Action Analyst Rating Change
May-09-23 Downgrade H.C. Wainwright Buy → Neutral
Mar-31-22 Resumed Piper Sandler Overweight
Mar-02-22 Resumed Cowen Outperform
Apr-12-21 Initiated Piper Sandler Overweight
Mar-01-21 Initiated Stifel Buy
Feb-26-21 Reiterated H.C. Wainwright Buy
Mar-10-20 Initiated The Benchmark Company Buy
Jan-17-19 Upgrade First Analysis Sec Neutral → Outperform
May-16-18 Initiated Stephens Overweight
Oct-13-17 Reiterated H.C. Wainwright Buy
May-31-17 Initiated Jefferies Buy
Jan-26-17 Downgrade First Analysis Sec Overweight → Equal-Weight
Jan-04-17 Upgrade Ladenburg Thalmann Neutral → Buy
Jan-06-16 Initiated H.C. Wainwright Buy
View All

Codexis Inc Stock (CDXS) Latest News

pulisher
10:07 AM

Codexis (NASDAQ:CDXS) Receives Overweight Rating from Cantor Fitzgerald - MarketBeat

10:07 AM
pulisher
Nov 22, 2024

Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings) - Benzinga

Nov 22, 2024
pulisher
Nov 22, 2024

Codexis (STU:4QK) EBITDA per Share : €-0.40 (TTM As of Sep. 2024) - GuruFocus.com

Nov 22, 2024
pulisher
Nov 21, 2024

Codexis (STU:4QK) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 21, 2024

Codexis (STU:4QK) 3-Year FCF Growth Rate : -35.00% (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024
pulisher
Nov 20, 2024

Codexis (STU:4QK) Forward Dividend Yield % : 0.00% (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 20, 2024

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire

Nov 20, 2024
pulisher
Nov 19, 2024

Codexis to Present at Piper Sandler Healthcare Conference in December 2024 | CDXS Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 15, 2024

Codexis (NASDAQ:CDXS) Given Overweight Rating at Cantor Fitzgerald - MarketBeat

Nov 15, 2024
pulisher
Nov 14, 2024

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Codexis Achieves 98% Efficiency in Breakthrough siRNA Synthesis Platform | CDXS Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Baillie Gifford & Co. Sells 895,002 Shares of Codexis, Inc. (NASDAQ:CDXS) - MarketBeat

Nov 14, 2024
pulisher
Nov 12, 2024

Codexis adds biotech veteran Raymond De Vré to board - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Codexis Strengthens Board and Updates Bylaws - TipRanks

Nov 12, 2024
pulisher
Nov 12, 2024

CDXSCodexis, Inc. Latest Stock News & Market Updates - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Codexis adds biotech veteran Raymond De Vré to board By Investing.com - Investing.com UK

Nov 12, 2024
pulisher
Nov 12, 2024

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Codexis Strengthens Board with Biotech Veteran Raymond De Vré, Former PolyPeptide CEO | CDXS Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Biofuel Enzymes Market Growth Surge: Key Players and Market - openPR

Nov 12, 2024
pulisher
Nov 11, 2024

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics - GlobeNewswire

Nov 11, 2024
pulisher
Nov 11, 2024

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for - The Bakersfield Californian

Nov 11, 2024
pulisher
Nov 11, 2024

Codexis to Showcase Breakthrough RNA Platform, Partners with Bachem at TIDES Europe 2024 | CDXS Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 08, 2024

Codexis Announces New Employment Inducement Grants - The Manila Times

Nov 08, 2024
pulisher
Nov 07, 2024

Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors - Simply Wall St

Nov 07, 2024
pulisher
Nov 06, 2024

Benchmark Downgrades Codexis (CDXS) - MSN

Nov 06, 2024
pulisher
Nov 06, 2024

CDXS (Codexis) PE Ratio : At Loss (As of Nov. 06, 2024) - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Codexis (FRA:4QK) 3-Year EBITDA Growth Rate : -26.40% (As of Sep. 2024) - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Benchmark Reaffirms “Hold” Rating for Codexis (NASDAQ:CDXS) - Defense World

Nov 06, 2024
pulisher
Nov 06, 2024

Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock By Investing.com - Investing.com Australia

Nov 06, 2024
pulisher
Nov 05, 2024

abrdn plc Grows Stock Holdings in Codexis, Inc. (NASDAQ:CDXS) - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

Codexis's SWOT analysis: enzyme engineering firm pivots to RNAi stock - Investing.com India

Nov 04, 2024
pulisher
Nov 04, 2024

Codexis to Participate in Upcoming Healthcare Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 04, 2024

Codexis (NASDAQ:CDXS) Earns Hold Rating from Benchmark - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Codexis, Inc. (NASDAQ:CDXS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$7.17 - Yahoo Finance

Nov 03, 2024
pulisher
Nov 03, 2024

Codexis, Inc. Announces Strong Third Quarter 2024 Financial Results - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

Codexis Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Nov 02, 2024
pulisher
Nov 02, 2024

Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Codexis, Inc. (NASDAQ:CDXS) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 02, 2024
pulisher
Nov 01, 2024

Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Codexis reports revenue growth and strategic focus in Q3 2024 - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Codexis Inc Q3 2024 Earnings: Revenue Hits $12.83M, Beating Esti - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Codexis Reports Strong Q3 Revenue Growth - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Codexis: Q3 Earnings Snapshot - CT Insider

Oct 31, 2024

Codexis Inc Stock (CDXS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):